ACTRN12622001200774招募中3 期
Conventional or Stereotactic Radiotherapy for the palliation of non-spine bone metastases: A randomised phase III trial.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 146
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Age 18 years or older
- •World Health Organisation Performance Status (WHO PS) 0-2
- •Histological confirmation of primary malignancy (exclude seminoma, Small Cell lung Cancer (SCLC) and haematological malignancies)
- •Able to consent to trial
- •Able to safely deliver SBRT and conventional radiotherapy to all sites of disease
- •Life expectancy >6 months
- •Able to complete QoL and pain questionnaires
- •1-3 Lesions <5cm in maximum dimension suitable for SBRT (excluding skull and mandible) with baseline pain score of at least 2 in target area. Lesions can be in close proximity and included in the one plan/treatment area if required.
- •Patients with spinal or intracranial metastases are eligible for inclusion but these sites will not be treated or assessed for the purpose of this trial
排除标准
- •Patients who are candidates for curative intent or disease-modifying treatment for oligometastatic disease
- •Patients unable or unwilling to comply with protocol requirements.
- •Pregnancy or trying to become pregnant
- •High fracture risk requiring fixation, Mirel’s score greater than or equal to 9
- •Chemotherapy or Immunotherapy within one week of radiotherapy
- •Previous radiotherapy at the treatment site(s).
研究者
相似试验
进行中（未招募）
2 期
SOPRANO - Stereotactic radiotherapy alone or stereotactic radiotherapy follow by niraparib treatment for ovarian cancer with progressive disease in three or less lesions, or recurrence of 3 or less metastatic lesions that had previously achieved complete response.Oligometastatic or oligoprogressive ovarian, fallopian tube or primary peritoneal carcinomaCancerISRCTN13282459Institute of Cancer Research Clinical Trial & Statistics Unit42
招募中
不适用
Potential abscopal effect of stereotactic body radiotherapy on the recurrence of hepatocellular carcinoma: An exploratory observation studyHepatocellular carcinomaJPRN-UMIN000038312ational Hospital Organization Nagasaki Medical Center280
招募中
不适用
Stereotactic Body Radiotherapy for the Management of Prostate Cancer Local RecurrencesC61Malignant neoplasm of prostateDRKS00030837Europäisches Radiochirurgie Centrum München50
已完成
2 期
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trialcancer spread to other parts of the bodymetastatic cancer10027476NL-OMON37922Vrije Universiteit Medisch Centrum20
进行中（未招募）
1 期
Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART)EUCTR2019-004952-13-BEniversity Hospital Ghent140